Creating therapeutic cancer vaccines: Notes from the battlefield

Trends in Immunology

Volumn 22, Issue 1, 2001, Pages 5-7

  Overwijk, Willem W ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; FREUND ADJUVANT; INTERLEUKIN 2; MELANOMA ANTIGEN;

APOPTOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLONAL ANERGY; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MELANOMA; NONHUMAN; SHORT SURVEY; T LYMPHOCYTE; TUMOR CELL; TUMOR ESCAPE;

EID: 0034922596     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(00)01793-2     Document Type: Review

References (33)

1. Cancer tumor antigens
2. A new era for cancer immunotherapy based on the genes that encode cancer antigens
3. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
4. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma
5. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
6. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
7. Vitiligo in patients with metastatic melanoma: A good prognostic sign
8. The new vaccines: Building viruses that elicit antitumor immunity
9. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
10. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen
11. + T cell response to influenza A viruses
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
14. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
15. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
16. Immune selection after antigen-specific immunotherapy of melanoma
17. + cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
18. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
19. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
20. A 'stealth effect': Adenocarcinoma cells engineered to express Trail elude tumor-specific and allogeneic T cell reactions
21. T cell clonal anergy
22. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death
23. TCR-mediated internalization of peptide-MHC complexes acquired by T cells
24. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes
25. Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands
26. Variant TCR ligands: New insights into the molecular basis of antigen-dependent signal transduction and T-cell activation
27. Regulatory T cells in autoimmmunity
28. Regulatory T cells: Key controllers of immunologic self-tolerance
29. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
30. Immune surveillance against a solid tumor fails because of immunological ignorance
31. The central role of CD4(+) T cells in the antitumor immune response
32. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
33. + T cell reactivity to a model tumor antigen